Name of journal: *World Journal of Diabetes*

ESPS Manuscript NO: 13432

Columns: Review

**Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment**

Balcıoğlu AS *et al.* Cardiac autonomic neuropathy in diabetes

Akif Serhat Balcıoğlu, Haldun Müderrisoğlu

**Akif Serhat Balcıoğlu,** Medical and Research Center of Alanya, Department of Cardiology, Başkent University, 07400 Alanya, Antalya, Turkey

**Haldun Müderrisoğlu,** Faculty of Medicine, Department of Cardiology, Başkent University, 06490 Ankara, Turkey

**Author contributions:** Balcıoğlu AS performed the literature search and wrote the paper; Müderrisoğlu H provided expert opinion and reviewed the article.

**Conflict-of-interest:** The authors confirm that the manuscript has no conflict of interest.

**Open-Access:** This article is an open-access article which selected by an in-house editor and fully peer-reviewed by external reviewers. It distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Akif Serhat Balcıoğlu, MD,** Medical and Research Center of Alanya, Department of Cardiology, Başkent University, Saray Mahallesi, Yunus Emre Caddesi, No:1, 07400 Alanya, Antalya, Turkey. [serhatbalcioglu@gmail.com](mailto:serhatbalcioglu@gmail.com)

**Telephone:** +90-242-5102525 **Fax:** +90-242-5115563

**Received:** August 22, 2014

**Peer-review started:** August 23, 2014

**First decision:** September 19, 2014

**Revised:** November 16, 2014

**Accepted:** November 27, 2014

**Article in press:**

**Published online:**

**Abstract**

Cardiac autonomic neuropathy (CAN) is a frequent chronic complication of diabetes mellitus with potentially life-threatening outcomes. CAN is caused by the impairment of the autonomic nerve fibers regulating heart rate, cardiac output, myocardial contractility, cardiac electrophysiology and blood vessel constriction and dilatation. It causes a wide range of cardiac disorders, including resting tachycardia, arrhythmias, intraoperative cardiovascular instability, asymptomatic myocardial ischemia and infarction and increased rate of mortality after myocardial infarction. Etiological factors associated with autonomic neuropathy include insufficient glycemic control, a longer period since the onset of diabetes, increased age, female sex and greater body mass index. The most commonly used methods for the diagnosis of CAN are based upon the assessment of heart rate variability (the physiological variation in the time interval between heartbeats), as it is one of the first findings in both clinically asymptomatic and symptomatic patients. Clinical symptoms associated with CAN generally occur late in the disease process and include early fatigue and exhaustion during exercise, orthostatic hypotension, dizziness, presyncope and syncope. Treatment is based on early diagnosis, life style changes, optimization of glycemic control and management of cardiovascular risk factors. Medical therapies, including aldose reductase inhibitors, angiotensin-converting enzyme inhibitors, prostoglandin analogs and alpha-lipoic acid, have been found to be effective in randomized controlled trials. The following article includes the epidemiology, clinical findings and cardiovascular consequences, diagnosis, and approaches to prevention and treatment of CAN.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Autonomic neuropathy; Cardiac; Cardiovascular reflex tests; Diabetes mellitus; Heart rate variability

**Core tip:** Although very frequent, cardiac autonomic neuropathy (CAN) is one of the most commonly overlooked complication of diabetes. Higher incidence of cardiovascular events is encountered with CAN due to its relation with silent myocardial ischemia, arrhythmias, intraoperative cardiovascular instability, orthostatic hypotension and cardiomyopathy. Diabetic patients should be screened for CAN due to the possibility of reversal of cardiovascular denervation in the early stages of the disease. Cardiovascular reflex tests and Holter-derived time- and frequency-domain measurements are frequently used for the diagnosis. Therapeutic approaches are promising and may hinder or reverse the progression of the disease when initiated during the early stages.

Balcıoğlu AS, Müderrisoğlu H. Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment. *World J Diabetes* 2014; In press

**INTRODUCTION**

Cardiac autonomic neuropathy (CAN), a type of generalized symmetric polyneuropathy, is the most examined and clinically significant diabetic autonomic neuropathy[1]. The autonomic nervous system has 2 major components: the parasympathetic and the sympathetic nervous systems. These may operate independently of each other or interact cooperatively to control heart rate, cardiac output, myocardial contractility, cardiac electrophysiology, and the constriction and dilatation of blood vessels[2]. CAN is caused by damage to the autonomic nerve fibers that innervate the heart and blood vessels and leads to abnormalities in cardiovascular dynamics[2]. The earliest finding of CAN, even at the subclinical stage, is a decrease in heart rate variability (HRV)[3].

**EPIDEMIOLOGY**

Diabetes is estimated to affect approximately 350 million people globally[4]. Diabetic neuropathies, including CAN, are frequent chronic complications of type 1 and 2 diabetes that influence quality of life and have potentially fatal outcomes[2]. Prevalence rates between 1.6% to 90% have been reported, varying according to the diagnostic methods used, population studied and disease stage[1]. The Diabetes Control and Complications Trial (DCCT) showed abnormal HRV values of 1.65%, 6.2% and 12.2% in patients with diabetes for a duration of less than 5 years, 5 to 9 years and more than 9 years, respectively[5]. A study including 1171 patients with both type of diabetes mellitus reported impaired HRV tests in 25.3% of type 1 and 34.3% of type 2 patients[6]. The different methodology between various studies makes epidemiological comparison difficult. Risk factors of decreased HRV in patients with type 2 diabetes include age, duration of diabetes, obesity and smoking[2]. In type 1 diabetes, risk factors of CAN include higher levels of HbA1c, hypertension, distal symmetrical polyneuropathy, retinopathy and hyperglycemic exposure[7,8].

**PATHOGENESIS**

Diabetic CAN is eventually caused by complex interactions among a number of pathogenic pathways. Hyperglycemia is the leading cause of the initiation of this pathogenic process[9,10]. The pathogenesis of diabetic CAN is multifactorial, including increased mitochondrial production of free radicals due to hyperglycemia-induced oxidative stress. Neuronal activity, mitochondrial function, membrane permeability and endothelial function are impacted by advanced glycosylation end product formation, polyol aldose reductase signaling and poly(ADP ribose) polymerase activation and the alteration of the Na+/K+-ATPase pump function. Neuronal apoptotic processes are precipitated by endoplasmic reticulum stress induced by hyperglycemia, along with impaired nerve perfusion, dyslipidemia, alterations in redox status, low-grade inflammation and disturbance in calcium balance[11]. The literature has described these mechanisms and their interactions but is beyond the scope of this article[9-11].

**CLINICAL MANIFESTATIONS**

Diabetes can lead to dysfunction in the autonomic nervous system, causing various cardiovascular disorders, including resting tachycardia, postural hypotension, higher intra/perioperative cardiovascular instability, more frequent asymptomatic myocardial ischemia and infarction, and greater mortality after myocardial infarction[2]. Clinical symptoms associated with CAN generally occur at later stages and include postural hypotension, dizziness, lightheadedness, presyncope, syncope, and early fatigue and exhaustion during exercise[1]. However, subclinical autonomic dysfunction, revealed as deterioration in HRV, can occur in the 1st year following diagnosis in patients with type 2 diabetes and within 2 years following diagnosis in type 1[12]. Low *et al*[13] reported a higher rate of autonomic symptoms in type 1 than in type 2 diabetes. A greater number of autonomic symptoms have been associated with an increased risk of CAN as measured by HRV[14].

Because neuropathy first affects the longest nerve fibers, the first manifestation of diabetic CAN tends to be related with vagus nerve damage, which is responsible for nearly 75% of parasympathetic activity[9]. This damage causes resting tachycardia as the sympathetic tone becomes dominant[15]. Tachycardia eventually diminishes in a few years due to progressive sympathetic nerve fiber damage. However, increased heart rate persists in these patients[16]. The progressive damage of the autonomic balance is indicated by additional symptoms, including intolerance to exercise, orthostatic hypotension and a further HRV reduction[17]. Cardiac pain perception often deteriorates with the involvement of sensory nerve fibers, making patients prone to silent ischemia and myocardial infarction[18,19].

Etiological factors associated with autonomic neuropathy include poor glycemic control, longer diabetes duration, increased age, female sex and greater body mass index[20]. Mortality rates of 25% to 50% within 5 to 10 years of diagnosis have been found in patients with symptomatic autonomic dysfunction[21,22]. Among diabetic patients, the 5-year mortality rate is 3 times higher in those with autonomic involvement than in those without[23].

**CARDIOVASCULAR CONSEQUENCES**

***Impaired heart rate variability***

HRV is a physiological variation in the interval between heartbeats and is regulated by the interaction of the sympathetic and parasympathetic tone[24]. The functional response to the instantaneous metabolic needs of the body is regulated by this beat-to-beat variation. As high variability reflects the cardiac ability to adapt and implies good health, damage or disturbances to this control system results in lower HRV values. Even in a normal heart rate, the first finding of CAN is a decrease in HRV, which is apparent at the subclinical stage and can be detected through deep respiration[25].

***Resting tachycardia***

Due to the dominant sympathetic tone, resting heart rates of 90 to 100 beats per minute with occasional increases to as many as 130 beats per minute are frequent findings in CAN with vagal impairment[16,26]. Highest resting heart rates have been shown in patients with lone parasympathetic impairment[16,26]. As the disease progresses and involves both parasympathetic and sympathetic nerves, the heart rate tends to return to the normal range but remains higher than in healthy individuals[16,26]. Tang *et al*[27] showed that resting heart rate is independently associated with CAN and has a high predictive value in predicting CAN in the general population[27]. A steady heart rate less responsive to exercise, stress or sleep is suggestive of almost total cardiac denervation, which indicates severe CAN[20].

***Exercise intolerance***

Exercise tolerance is worsened by CAN through the blunting of the increases in heart rate, blood pressure and cardiac output response to exertion[20]. The development of hypotension or hypertension following strenuous exercise is more likely in individuals with CAN, particularly in the onset of a new exercise program[1]. Therefore, patients with diabetes probably to have CAN should be checked for cardiac stress before beginning to exercise[1]. Due to poor thermoregulation, such patients should avoid exercising in environments that are too hot or cold and hydrate adequately[1].

***Intraoperative and perioperative cardiovascular instability***

The perioperative risk of cardiovascular morbidity and mortality are 2 to 3 times higher in diabetic individuals[28]. Since the normal autonomic response of vasoconstriction and the increase in heart rate cannot appropriately compensate for the vasodilatation and negative chronotropic effects of anesthesia, diabetic patients with CAN are subject to more pronounced decreases in blood pressure and heart rate during induction of anesthesia and, to a lesser extent, after intubation and extubation[20,28]. In addition, more severe intraoperative hypothermia in patients with CAN resulting in decelerated metabolism of anesthetic drugs may cause deepening of anesthesia and/or delayed recovery[29]. Accordingly, screening for CAN is recommended during the preoperative evaluation of diabetic patients for anesthetic management planning.

***Non-dipping blood pressure profile and orthostatic hypotension***

Blood pressure has diurnal variations. Decreases in nighttime and increases in daytime blood pressure show its circadian rhythm[30]. Declines in parasympathetic tone occur at night and nocturnal unopposed sympathetic activity leads to deterioration of the circadian rhythm of blood pressure and results in the lack of or a less than 10% reduction in nocturnal blood pressure in patients with CAN[31]. Such “non-dipper” CAN subjects experience more frequent left ventricular hypertrophy and are predisposed to cardiovascular events[32]. Another blood pressure regulation abnormality related to CAN is orthostatic hypotension, which is defined as a decrease in systolic blood pressure by a minimum of 20 mmHg (at least 30 mmHg in patients with hypertension) or diastolic blood pressure of 10 mmHg in response to postural shifts from the supine to the standing[2,20]. In diabetic individuals, orthostatic hypotension develops as a consequence of denervation of the efferent sympathetic vasomotor nerves, especially in the splanchnic vascular bed[33]. Additionally, pathogenesis of orthostatic hypotension includes lower cutaneous, splanchnic and total vascular resistance[10]. Impaired chronotropic and/or blood pressure response to exercise may accompany this condition[10]. Orthostatic hypotension can cause many symptoms that reduce quality of life or lead to serious injury due to falling, such as lightheadedness, dizziness, faintness, visual blurring, presyncope and syncope while standing[20]. However, an important number of patients are asymptomatic despite significant decreases in blood pressure[2]. Orthostatic hypotension can be provoked by several drugs, which may be used concurrently for treatment of diabetes or its complications, including, vasodilators, diuretics, phenothiazines, insulin (through endothelium-dependent vasodilation) and tricyclic antidepressants for symptomatic relief of pain associated with diabetic neuropathy[9].

***Silent myocardial ischemia***

Coronary artery disease has long been considered as a major complication of diabetes mellitus[34]. Numerous studies have reported more extensive atherosclerotic disease, particularly that of the coronary arteries, in diabetic individuals[35,36]. Silent myocardial ischemia is defined as the objective documentation of myocardial ischemia without angina or its equivalents[37]. Several reports have shown the predictive role of silent ischemia during exercise testing[38] or ambulatory electrocardiography (ECG) monitoring[39] on poor clinical outcomes and survival. A threefold increase in cardiac deaths was witnessed over a 2-year follow-up in individuals with silent ischemia during ambulatory ECG monitoring[39]. Painless presentation of myocardial infarction in patients with CAN may include diaphoresis, dyspnea, fatigue, lightheadedness, palpitations, acute confusion, indigestion, nausea, and vomiting[20]. Several explanations are possible for the variety of symptom patterns in individuals with diabetes, such as various pain perception thresholds, sensorial denervation secondary to autonomic neuropathy and psychological disavowal[34]. Therefore, despite increasing ischemia, individuals with CAN and coronary artery disease may resume exercise as the longer threshold or subthreshold ischemia is not sufficient to induce pain, thus endangering the patient[40]. Likewise, the Framingham Heart Study reported higher incidences of painless myocardial infarction in patients with diabetes than without (39% *vs* 22%)[41,42]. Similarly, the National Registry of Myocardial Infarction 2 (NRMI-2) survey found that one-third of patients presented without angina[43]. In the NRMI-2, diabetes was present in 32% of subjects without chest pain and 25.4% with angina[43]. The Detection of Ischemia in Asymptomatic Diabetic Study, including 1123 patients with type 2 diabetes, reported that CAN is able to strongly predict silent ischemia and succeeding adverse cardiovascular events[44]. Vinik *et al*[10], in their meta-analysis of 12 studies, reported the association between CAN and the existence of silent ischemia detected by exercise stress tests with prevalence rate ratios of 0.85 to 15.53[10]. Therefore, patients with CAN require more rigorous evaluation of the presence of coronary artery disease. The presence and extent of macrovascular coronary artery disease in such patients can be noninvasively tested by resting and stress thallium myocardial scintigraphy[1]. Moreover, cardiovascular autonomic function testing should be included in the coronary artery risk assessment of all diabetic patients.

***Myocardial infarction and increased risk of mortality***

Myocardial infarction tends to be more extensive and severe in patients with diabetes[42,45]. The timely diagnosis of myocardial ischemia or infarction is often delayed due to diminished angina perception and therefore the period before first medical contact is prolonged[46]. Long-term survival rates following acute myocardial infarction are lower in patients with diabetes[20]. In diabetic patients, 5-year survival rates of 38% have been reported following the first major coronary event, lowering to just 25% for those with subsequent events, while the rates are 75% and 50%, respectively, in non-diabetic patients[45,47]. HRV has been demonstrated to be a good predictor of post-myocardial infarction mortality[48-50]. For this reason, cardiovascular autonomic function testing is advisable for all diabetic patients after a myocardial infarction to identify the candidates who have a high risk of death[51].

***Sudden death***

CAN is associated with a higher risk of malignant arrhythmias and sudden death[9]. Previous studies have found 5-year mortality rates between 16% and 50% in patients with both CAN and either type of diabetes, often attributed to sudden cardiac death[14,23]. Severe asymptomatic ischemia inducing fatal arrhythmias has been reported as the leading potential cause[22]. Additionally, life-threatening arrhythmias and sudden death may be predisposed by QT prolongation[52]. The European Diabetes Insulin-Dependent Diabetes Mellitus (EURODIAB IDDM) Complications Study established the association between impaired HRV and corrected QT prolongation[53]. In addition, unopposed increases in sympathetic activity and resultant norepinephrine signaling and metabolism[9], along with increased mitochondrial oxidative stress[54] and calcium-dependent apoptosis[55], is thought to contribute to myocardial injury[54,56] and clarify the higher risk of sudden cardiac events and deaths. The EURODIAB IDDM Prospective Cohort Study, including 2787 patients with type 1 diabetes, reported CAN to be the strongest predictor of mortality over the 7-year follow-up period, even greater than traditional cardiovascular risk factors[57]. A meta-analysis including 15 studies and 2900 diabetic patients showed CAN patients to have a pooled relative risk of mortality of 3.45 (95%CI: 2.66-4.47) and an increase in line with higher numbers of cardiovascular autonomic function abnormalities[58]. Similar results were confirmed in 2 other studies of patients with type 1 and type 2 diabetes, strengthening the role in predicting mortality of abnormalities in both HRV and the QT index independent of conventional risk factors[59,60]. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial[61] also confirmed the association between CAN and mortality in type 2 diabetic patients. In this trial, Pop-Busui *et al*[62] showed that mortality was between 1.55 and 2.14 times more likely in patients with baseline CAN than those without[62]. Three large studies (the ACCORD trial[61], the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation trial[63], and the Veterans Affairs Diabetes Trial[64]) investigated the role of more intensive treatment and the frequency of cardiovascular events on individuals with long-term type 2 diabetes. In these trials, tight glycemic control was not shown to reduce cardiovascular adverse events[2] and the ACCORD trial was terminated early due to the increased mortality risk in the intensive therapy group[65]. Hypoglycemia is known to reduce the threshold for malignant ventricular arrhythmias that can result in sudden death[9,66]. In addition, hypoglycemic periods were reported to lead to impaired autonomic cardiovascular function even in healthy volunteers[67]. Hence, the cause of a lack of a decrease, or even an increase, in cardiovascular events in the intensive therapy arm may be linked to deterioration of cardiac autonomic function due to episodes of hypoglycemia.

***Cardiomyopathy***

Diabetic cardiomyopathy is defined as structural and functional myocardial abnormalities without coronary artery disease, hypertension or valvular heart disease[68]. It is characterized by diastolic dysfunction[69]. The responsible mechanisms are left ventricular hypertrophy (increased left ventricular mass and concentric remodeling[70]), myocardial lipotoxicity, increased oxidative stress, cell death, interstitial and perivascular fibrosis, impaired contractile reserve, changes in myocardial substrate and energy metabolism, altered substrate utilization and mitochondrial dysfunction[69]. In patients with CAN, the initial augmentation in cardiac sympathetic activity stimulates the renin-angiotensin-aldosterone system and increases heart rate, stroke volume and peripheral vascular resistance[71]. In addition, the combination of sympathetic hyperactivity and regional myocardial sympathetic denervation cause reduced coronary blood flow and diastolic dysfunction, which may lead to impairment of systolic function[2].

***Stroke***

Previous studies have revealed the relationship between CAN and cerebrovascular events. Ko *et al*[72] reported that the presence of CAN, assessed by HRV testing, was significantly associated with the ischemic stroke in a study of 1458 patients with type 2 diabetes with a 7-year follow-up[72]. Another study of 133 subjects with type 2 diabetes showed that stroke could be predicted by parasympathetic and sympathetic autonomic function abnormalities[73].

**DIAGNOSTIC METHODS of CARDIAC AUTONOMIC NEUROPATHY**

Variability in heart rate and blood pressure values can provide data regarding both parasympathetic and sympathetic autonomic function and is useful in clinical settings.

***Heart rate variability***

The most commonly used methods for the diagnosis of CAN are based on HRV assessment. HRV testing is noninvasive and objective in the evaluation of cardiac autonomic function and can be performed by recording electrocardiograms during deep breathing, standing, and Valsalva maneuvers[74]. HRV analysis enables the independent measurement of the sympathetic and parasympathetic components of the autonomic nervous system and can be assessed with a number of simple clinical tests[75] or easier digital 24-h electrocardiographic recordings[24]. In the 1970s, Ewing *et al*[75] discovered 5 simple tests of short-term R-R alterations to identify CAN in patients with diabetes: (1) heart rate response to respiration, which measures beat to beat sinus arrhythmia (R-R variation) during paced deep expiration and inspiration (E:I ratio); (2) heart rate response to standing, known as the 30:15 ratio, which is the ratio of the longest R-R interval (between beats 20to 40) to the shortest R-R interval (between beats 5 to 25); (3) the Valsalva maneuver, measuring the heart rate response during and after a provoked increase in intra-thoracic and intra-abdominal pressures; (4) blood pressure response to orthostasis, which evaluates baroreflex mediated blood pressure fluctuations after changes in posture; and (5) blood pressure response to isometric exercise, as defined by the diastolic blood pressure increase due to continuous muscle contraction using a handgrip dynamometer[75]. Tests 1 and 2 reflect parasympathetic function, and 4 and 5, sympathetic function[76,77]. Although the Valsalva ratio primarily represents parasympathetic activity, the resultant autonomic changes are complicated and include both the sympathetic and parasympathetic components[78]. An American Diabetes Association statement describes these validated cardiac autonomic reflex tests (CART) in detail and recommends their use in the diagnosis of CAN (Table 1)[1]. HRV with deep breathing is the most commonly used autonomic function test and has a specificity of approximately 80%[79,80].

The assessment of HRV has become easier and more detailed due to new, digital, high frequency, 24-hour multi-channel electrocardiographic recorders and the use of statistical indexes in the time and frequency domains.

***Time domain methods***

Time domain methods determine the heart rate at any point in time or the intervals between consecutive normal complexes[24]. Each QRS complex is detected and the normal-to-normal (NN) intervals (that is all intervals between adjacent QRS complexes resulting from sinus node depolarizations) or the instantaneous heart rate is determined through a continuous ECG record[24]. Simple time-domain variables that can be analyzed include mean NN interval, mean heart rate, the difference between the longest and the shortest NN interval and the variation between night and day heart rate[24]. More complex time-domain parameter calculations can be performed from a series of instantaneous heart rates or cycle intervals, particularly those recorded during 24-h periods[24]. The complex parameters can be divided into 2 classes: those derived from direct measurements of the NN intervals and those derived from the differences between NN intervals. The parameters calculated by direct measurements include: standard deviation of the NN interval (SDNN), reflecting all cyclic components responsible for variability in the recording period; standard deviation of the average NN interval (SDANN) calculated over periods (usually 5 min), estimating heart rate changes from cycles longer than 5 min; and the mean of the 5-min standard deviation of the NN interval (SDNN index) calculated over 24 h, measuring variability from cycles of less than 5 min. Secondly, the parameters calculated by the differences between NN intervals include the square root of the mean squared differences of successive NN intervals (RMSSD), the number of interval differences of successive NN intervals of more than 50 msec (NN50), and the division of NN50 by the total number of NN intervals (pNN50)[24]. Although influenced by several arrhythmias and requiring normal sinus rhythm and atrioventricular nodal function, these short-term variation measurements estimate high frequency variations in heart rate and are therefore highly correlated[24]. SDNN represents both the sympathetic and parasympathetic modulation of HRV, and RMSSD and pNN50 the parasympathetic system[24].

***Frequency domain methods***

CAN may also be evaluated using spectral analysis of HRV, which divides the R-R signal into sine and cosine waves to estimate the amount of variability as a function of frequency[24]. Three main spectral components are distinguished in a spectrum calculated from short-term recordings of 2 to 5 min: very-low-frequency (≤ 0.04 Hz) of fluctuations in vasomotor tone related to thermoregulation, low-frequency (0.04-0.15 Hz) associated with the baroreceptor reflex, and high-frequency (0.15-0.4 Hz) related to respiratory activity[24]. The sympathetic system is thought to modulate the 2 low-frequency components and the parasympathetic system the high-frequency component[20]. Accordingly, while decreases in very-low- and low-frequency peaks indicate sympathetic dysfunction, a decrease in the high-frequency peak is a sign of parasympathetic dysfunction[1]. A decrease in the ratio of low-frequency-to-high-frequency demonstrates sympathetic imbalance[1]. Various mathematical methods can be used to analyze the spectral components of HRV. Most common is the Fourier transform because of its simplicity and high processing speed[24]. A noise-free signal is necessary in order to correctly perform the spectral analysis. Because artefacts and extra beats must be removed, this correction leads to data loss and is associated with an underestimation in each case. Additionally, specific reference values must be obtained as each HRV-analysing device has different technical properties for spectral measurements.

It is not yet clear which of these 2 methods is preferable: time-domain methods including the standardized CART of Ewing or frequency-domain methods. However, many time- and frequency-domain variables obtained over the 24-h period are highly correlated with each other[24]. On the other hand, studies comparing Holter-based analysis and CART found a high (83%) correlation between the both techniques[81]. The advantages of Holter-based techniques include simpler, less stressful and faster implementation during daily routine use, independence of patient cooperation and greater sensitivity allowing for the identification of disorders in the early stages. However, CART can be applied quickly (less than 15 min) using stand-alone operator friendly devices during routine physical examination.

***Heart rate turbulence***

Another Holter-based technique for evaluating CAN is the heart rate turbulence (HRT)[82]. HRT refers to sinus rhythm cycle length fluctuations following isolated premature ventricular beats. After an initial acceleration, the sinus rate decelerates after a premature ventricular beat. There are 2 components of HRT; turbulence onset and turbulence slope. A transient vagal inhibition triggers the mentioned initial acceleration in heart rate as a response to the missed baroreflex afferent input due to hemodynamically ineffective ventricular contraction. The successive deceleration in heart rate is caused by a sympathetically mediated overshoot of arterial pressure through vagal recruitment[82]. HRT evaluation can be used in the risk assessment after acute myocardial infarction and in the monitoring of disease progression in heart failure and CAN[82]. We previously demonstrated that among HRV and HRT indexes, turbulence slope has the greatest correlation with CAN severity[83]. A turbulence slope of below 3.32 msec/R-R is 97% sensitive and 71% specific for the diagnosis of CAN as detected by the CART in patients with type 2 diabetes[83].

***Other diagnostic tools***

Other methods currently used in research settings are scintigraphic evaluation of sympathetic innervation of the heart, which can reveal cardiac sympathetic nerve population changes and early anatomical regional deficits of sympathetic denervation[84-86]; microneurography, which records electrical activity released by peroneal, tibial or radial sympathetic nerves and identifies sympathetic dysfunction[87]; neurovascular flow, using noninvasive laser Doppler measures of peripheral sympathetic reactions to nociception[88]; and baroreflex sensitivity, which evaluates the capability to reflexively increase vagal activity in response to a sudden increase in blood pressure[89]. As many of these tests assess the influence on sympathetic component, they do not provide information about early stage CAN. In a recent study, it was shown that altered cardiac autonomic balance can be detected through exercise stress testing in diabetic subjects even with minimal evidence of CAN[90].

***Criteria for diagnosis and staging***

CARTs are the gold standard clinical tests for cardiovascular autonomic neuropathy[91]. Following the 8th international symposium on diabetic neuropathy in 2010, criteria for diagnosis and staging of CAN are defined in the CAN Subcommittee of the Toronto Consensus Panel statement[92]. Accordingly, only 1 abnormal CART result is sufficient to diagnose possible or early CAN; among the 7 autonomic function analysis (5 CART, time-domain and frequency-domain HRV tests), 2 or 3 abnormal tests indicate definite or confirmed CAN; and severe/advanced CAN can be indicated by concurrent orthostatic hypotension[91].

**SCREENING FOR CAN**

By the time clinical signs occur, CAN has often reached to a late stage, making management more difficult. Therefore, patients should be screened for CAN at the time of diagnosis of type 2 diabetes and within 5 years of diagnosis of type 1 diabetes (except presence of symptoms suggesting autonomic neuropathy earlier)[1]. In addition, screening may be of benefit before undergoing an operation or beginning a new intense exercise program[93,94]. Screening should include a clinical history and an evaluation for evidence of autonomic dysfunction. Main HRV tests (E:I ratio, heart rate response to Valsalva maneuver, and heart rate response to standing) should also be performed. As an alternative to CART, easier screening methods has been attempted to develop. For instance, sudomotor function tests that assess the cholinergic innervation of sweat glands have been found to be useful for early screening of CAN[95]. Ge *et al*[96] offered a new risk score system not requiring specific tests for screening CAN, using clinical parameters including age, body mass index, hypertension and resting heart rate. The risk score can be between 0 and 15, and a score of 6 can detect CAN in 72.87% of previously undiagnosed individuals[96]. Screening should be repeated annually in the presence of negative results[1].

**THERAPEUTIC APPROACHES**

Early determination of CAN is significant for the success of therapeutic strategies as cardiovascular denervation seems to be reversible at onset[97]. In less affected patients, lifestyle changes including graded supervised exercise associated with weight loss improve HRV[97].

***Optimizing glycemic control***

Blood glucose optimization is the essential treatment for CAN. The Framingham Heart Study showed the significant association between reduced HRV and increased fasting plasma glucose level[98]. This finding is present in diabetics as well as individuals with impaired glucose tolerance[99]. Additionally, the DCCT reported that intensive insulin therapy reduced the incidence of CAN in comparison to conventional insulin therapy after approximately 5 years (14% *vs* 7%; *P* < 0.004) in type 1 diabetics[100]. The Epidemiology of Diabetes Intervention and Complication Study (EDIC) is a longitudinal cohort follow-up study for the DCCT[101]. Pop-Busui *et al*[102] demonstrated that during EDIC follow-up, CAN progressed in both the conventional and intensive insulin therapy groups, while its incidence and prevalence remained lower in the intensive therapy group despite similar glycemic control[102]. Accordingly, the early initiation of intensive glucose control in type 1 diabetics can help to minimize the development of CAN[102]. On the other hand, the benefit of glycemic control in type 2 diabetics is less certain[1,2]. The VA Cooperative Study reported a similar prevalence of autonomic neuropathy in type 2 diabetics after 2 years of intense glucose control in comparison with conventional glycemic control[103]. Similarly, in the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen Detected Diabetes in Primary Care Danish arm, CAN was frequently found 6 years following diagnosis of type 2 diabetes and this prevalence was not significantly affected by intensive multifactorial treatment in comparison with routine care[104]. Conversely, in the Steno-2 Trial patients with type 2 diabetes were given intensive multifactorial treatment (*e.g.*, targeting hyperglycemia, hypertension and dyslipidemia, including acetylsalicylic acid for secondary prevention) and targeted strict glycemic control as well as other cardiovascular risk factor modification, which reduced the incidence of autonomic dysfunction by approximately 60%[105]. Briefly, the intensive blood glucose, HbA1c, blood pressure and lipid levels control using pharmacological therapy with lifestyle changes are recommended for all diabetic patients[1].

***Other therapies***

Functional disorders of the autonomic nervous system can be treated with a variety of medications. In a trial including 73 type 2 diabetic subjects, a four-month period of treatment with alpha-lipoic acid, which reduces oxygen free radicals, improved HRV detected by standardized CART[1,106]. While the use of aldose reductase inhibitors (epalrestat, fidarestat and AS-3201), which reduce nerve sorbitol, had a positive influence on HRV in patients with mild abnormalities, they were ineffective in advanced CAN patients[1,107]. Total HRV has been shown to be increased and parasympathetic/sympathetic balance improved by angiotensin-converting enzyme (ACE) inhibition in patients with mild autonomic neuropathy through increases in nerve blood flow[1]. Prostoglandin analogs have been shown to be effective through the same mechanism[1]. Cardioselective beta-blockers are considered to have positive effects on autonomic dysfunction. For example, the addition of metoprolol to ramipril therapy in patients with type 1 diabetes resulted in recovery of HRV parameters[108]. Furthermore, bisoprolol improved HRV in heart failure[109]. In a study including individuals with long-term diabetes and diabetic neuropathy, the combination of ACE inhibition and angiotensin-receptor blockade improved autonomic neuropathy[110]. In addition, Ozdemir *et al*[111] showed that losartan therapy significantly improved HRV in patients with ischemic cardiomyopathy already receiving ACE inhibitors and beta-blockers. Similarly, sympathovagal imbalance in heart failure patients was improved following the administration of spironolactone along with enalapril, furosemide, and digoxin[112]. Such evidence reveals that combination therapies appear to provide better results than monotherapies.

***Orthostatic hypotension***

Because orthostatic hypotension is a relatively late complication of CAN, the treatment is challenging due to advanced disease. Nonpharmacological treatments include: increased water consumption; the use of lower-extremity stockings; avoidance of sudden postural changes to standing up; avoidance of medicines such as vasodilators, diuretics, phenothiazines and tricyclic antidepressants that provoke hypotension; eating frequent, small meals to prevent postprandial hypotension; and avoidance of exercises and maneuvers that increase intra-abdominal and intra-thoracic pressure resulting in venous return decrease[20]. Some physical preventive maneuvers, such as crossing of the legs and squatting may counter decreases in blood pressure[9]. While pharmacological treatments, such as midodrine, clonidine, octreotide, fludrocortisone acetate, erythropoietin, nonselective beta-blockers and prydostigmine bromide appear promising, all have mild to severe side effects, including hypertension[9].

**CONCLUSION**

Although very common and serious, CAN is a frequently overlooked complication of diabetes. Related with intraoperative and perioperative cardiovascular instability, abnormal blood pressure profile, orthostatic hypotension, silent myocardial ischemia, arrhythmias, diabetic cardiomyopathy, and stroke, CAN is associated with significant increases in morbidity and mortality. Patients may have subclinical CAN for several years before it becomes clinically apparent. Because the progression of cardiovascular denervation is partly reversible or can be slowed down in the early stages of the disease, recent guidelines strongly recommend screening for CAN in patients with diabetes. Assessment of CAN is possible through a variety of methods, such as CART, HRV and imaging modalities. Operator friendly devices and use of Holter-based analysis has simplified CAN testing. Treatment principles include early diagnosis, optimization of glycemic control, life style changes and management of cardiovascular risk factors. Medical therapy, including aldose reductase inhibitors, ACE inhibitors, prostoglandin analogs and alpha-lipoic acid, have been found to be effective in randomized control trials for the treatment of autonomic neuropathies. Orthostatic hypotension, which may lead to life-threatening injuries, is an undesired manifestation and indicates severe or advanced CAN.

**REFERENCES**

1 **Boulton AJ**, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care* 2005; **28**: 956-962 [PMID: 15793206 DOI: 10.2337/diacare.28.4.956]

2 **Vinik AI**, Erbas T. Diabetic autonomic neuropathy. *Handb Clin Neurol* 2013; **117**: 279-294 [PMID: 24095132 DOI: 10.1016/B978-0-444-53491-0.00022-5]

3 **Ewing DJ**, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. *Q J Med* 1980; **49**: 95-108 [PMID: 7433630]

4 **World Health Organization**. Diabetes Programme. Available from: URL: http: //www.who.int/diabetes/en/

5 **The Diabetes Control and Complications Trial Research Group.** The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). *Diabetologia* 1998; **41**: 416-423 [PMID: 9562345 DOI: 10.1007/s001250050924]

6 **Ziegler D**, Dannehl K, Mühlen H, Spüler M, Gries FA. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. *Diabet Med* 1992; **9**: 806-814 [PMID: 1473320 DOI: 10.1111/j.1464-5491.1992.tb01898.x]

7 **Witte DR**, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. *Diabetologia* 2005; **48**: 164-171 [PMID: 15619072 DOI: 10.1007/s00125-004-1617-y]

8 **Ziegler D**, Zentai C, Perz S, Rathmann W, Haastert B, Meisinger C, Löwel H. Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. *Exp Clin Endocrinol Diabetes* 2006; **114**: 153-159 [PMID: 16710813 DOI: 10.1055/s-2006-924083]

9 **Pop-Busui R**. Cardiac autonomic neuropathy in diabetes: a clinical perspective. *Diabetes Care* 2010; **33**: 434-441 [PMID: 20103559 DOI: 10.2337/dc09-1294]

10 **Vinik AI**, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. *Diabetes Care* 2003; **26**: 1553-1579 [PMID: 12716821 DOI: 10.2337/diacare.26.5.1553]

11 **Albers JW**, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. *Curr Neurol Neurosci Rep* 2014; **14**: 473 [PMID: 24954624 DOI: 10.1007/s11910-014-0473-5]

12 **Pfeifer MA**, Weinberg CR, Cook DL, Reenan A, Halter JB, Ensinck JW, Porte D. Autonomic neural dysfunction in recently diagnosed diabetic subjects. *Diabetes Care* 1984; **7**: 447-453 [PMID: 6499637 DOI: 10.2337/diacare.7.5.447]

13 **Low PA**, Benrud-Larson LM, Sletten DM, Opfer-Gehrking TL, Weigand SD, O'Brien PC, Suarez GA, Dyck PJ. Autonomic symptoms and diabetic neuropathy: a population-based study. *Diabetes Care* 2004; **27**: 2942-2947 [PMID: 15562211 DOI: 10.2337/diacare.27.12.2942]

14 **Navarro X**, Kennedy WR, Sutherland DE. Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. *Diabetologia* 1991; **34** Suppl 1: S108-S112 [PMID: 1936671 DOI: 10.1007/BF00587633]

15 **Schönauer M**, Thomas A, Morbach S, Niebauer J, Schönauer U, Thiele H. Cardiac autonomic diabetic neuropathy. *Diab Vasc Dis Res* 2008; **5**: 336-344 [PMID: 18958844 DOI: 10.3132/dvdr.2008.047]

16 **Ewing DJ**, Campbell IW, Clarke BF. Heart rate changes in diabetes mellitus. *Lancet* 1981; **1**: 183-186 [PMID: 6109858 DOI: 10.1016/S0140-6736(81)90061-1]

17 **Ziegler D**. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. *Diabetes Metab Rev* 1994; **10**: 339-383 [PMID: 7796704 DOI: 10.1002/dmr.5610100403]

18 **Airaksinen KE**, Koistinen MJ. Association between silent coronary artery disease, diabetes, and autonomic neuropathy. Fact of fallacy? *Diabetes Care* 1992; **15**: 288-292 [PMID: 1547688]

19 **Marchant B**, Umachandran V, Stevenson R, Kopelman PG, Timmis AD. Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes. *J Am Coll Cardiol* 1993; **22**: 1433-1437 [PMID: 8227802 DOI: 10.1016/0735-1097(93)90554-E]

20 **Vinik AI**, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation* 2007; **115**: 387-397 [PMID: 17242296 DOI: 10.1161/CIRCULATIONAHA.106.634949]

21 **Ewing DJ**, Boland O, Neilson JM, Cho CG, Clarke BF. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. *Diabetologia* 1991; **34**: 182-185 [PMID: 1884890 DOI: 10.1007/BF00418273]

22 **Rathmann W**, Ziegler D, Jahnke M, Haastert B, Gries FA. Mortality in diabetic patients with cardiovascular autonomic neuropathy. *Diabet Med* 1993; **10**: 820-824 [PMID: 8281726 DOI: 10.1111/j.1464-5491.1993.tb00173.x]

23 **O'Brien IA**, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. *Q J Med* 1991; **79**: 495-502 [PMID: 1946930]

24 Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Circulation* 1996; **93**: 1043-1065 [PMID: 8598068 DOI: 10.1161/01.CIR.93.5.1043]

25 **Metelka R**. Heart rate variability - current diagnosis of the cardiac autonomic neuropathy. A review. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2014; **158**: 327-338 [PMID: 25004914 DOI: 10.5507/bp.2014.025]

26 **Pop-Busui R**. What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes. *J Cardiovasc Transl Res* 2012; **5**: 463-478 [PMID: 22644723 DOI: 10.1007/s12265-012-9367-6]

27 **Tang ZH**, Zeng F, Li Z, Zhou L. Association and predictive value analysis for resting heart rate and diabetes mellitus on cardiovascular autonomic neuropathy in general population. *J Diabetes Res* 2014; **2014**: 215473 [PMID: 24772443 DOI: 10.1155/2014/215473]

28 **Burgos LG**, Ebert TJ, Asiddao C, Turner LA, Pattison CZ, Wang-Cheng R, Kampine JP. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. *Anesthesiology* 1989; **70**: 591-597 [PMID: 2929996 DOI: 10.1097/00000542-198904000-00006]

29 **Kitamura A**, Hoshino T, Kon T, Ogawa R. Patients with diabetic neuropathy are at risk of a greater intraoperative reduction in core temperature. *Anesthesiology* 2000; **92**: 1311-1318 [PMID: 10781276 DOI: 10.1097/00000542-200005000-00019]

30 **Furlan R**, Guzzetti S, Crivellaro W, Dassi S, Tinelli M, Baselli G, Cerutti S, Lombardi F, Pagani M, Malliani A. Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. *Circulation* 1990; **81**: 537-547 [PMID: 2297860 DOI: 10.1161/01.CIR.81.2.537]

31 **Spallone V**, Bernardi L, Ricordi L, Soldà P, Maiello MR, Calciati A, Gambardella S, Fratino P, Menzinger G. Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. *Diabetes* 1993; **42**: 1745-1752 [PMID: 8243821 DOI: 10.2337/diab.42.12.1745]

32 **Schwartz PJ**, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. *Circulation* 1992; **85**: I77-I91 [PMID: 1728509]

33 **Low PA**, Walsh JC, Huang CY, McLeod JG. The sympathetic nervous system in diabetic neuropathy. A clinical and pathological study. *Brain* 1975; **98**: 341-356 [PMID: 810214 DOI: 10.1093/brain/98.3.341]

34 **Chiariello M**, Indolfi C. Silent myocardial ischemia in patients with diabetes mellitus. *Circulation* 1996; **93**: 2089-2091 [PMID: 8925575 DOI: 10.1161/01.CIR.93.12.2089]

35 **Dortimer AC**, Shenoy PN, Shiroff RA, Leaman DM, Babb JD, Liedtke AJ, Zelis R. Diffuse coronary artery disease in diabetic patients: fact or fiction? *Circulation* 1978; **57**: 133-136 [PMID: 618380 DOI: 10.1161/01.CIR.57.1.133]

36 **Garcia MJ**, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. *Diabetes* 1974; **23**: 105-111 [PMID: 4359625]

37 **Cohn PF**, Fox KM, Daly C. Silent myocardial ischemia. *Circulation* 2003; **108**: 1263-1277 [PMID: 12963683 DOI: 10.1161/01.CIR.0000088001.59265.EE]

38 **Weiner DA**, Ryan TJ, McCabe CH, Luk S, Chaitman BR, Sheffield LT, Tristani F, Fisher LD. Significance of silent myocardial ischemia during exercise testing in patients with coronary artery disease. *Am J Cardiol* 1987; **59**: 725-729 [PMID: 3825930 DOI: 10.1016/0002-9149(87)91081-2]

39 **Deedwania PC**, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. *Circulation* 1990; **81**: 748-756 [PMID: 2306826 DOI: 10.1161/01.CIR.81.3.748]

40 **Shakespeare CF**, Katritsis D, Crowther A, Cooper IC, Coltart JD, Webb-Peploe MW. Differences in autonomic nerve function in patients with silent and symptomatic myocardial ischaemia. *Br Heart J* 1994; **71**: 22-29 [PMID: 8297687 DOI: 10.1136/hrt.71.1.22]

41 **Kannel WB**, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. *N Engl J Med* 1984; **311**: 1144-1147 [PMID: 6482932 DOI: 10.1056/NEJM198411013111802]

42 **Margolis JR**, Kannel WS, Feinleib M, Dawber TR, McNamara PM. Clinical features of unrecognized myocardial infarction--silent and symptomatic. Eighteen year follow-up: the Framingham study. *Am J Cardiol* 1973; **32**: 1-7 [PMID: 4713110 DOI: 10.1016/S0002-9149(73)80079-7]

43 **Canto JG**, Shlipak MG, Rogers WJ, Malmgren JA, Frederick PD, Lambrew CT, Ornato JP, Barron HV, Kiefe CI. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. *JAMA* 2000; **283**: 3223-3229 [PMID: 10866870 DOI: 10.1001/jama.283.24.3223]

44 **Wackers FJ**, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. *Diabetes Care* 2004; **27**: 1954-1961 [PMID: 15277423 DOI: 10.2337/diacare.27.8.1954]

45 **Weitzman S**, Wagner GS, Heiss G, Haney TL, Slome C. Myocardial infarction site and mortality in diabetes. *Diabetes Care* 1982; **5**: 31-35 [PMID: 7140497 DOI: 10.2337/diacare.5.1.31]

46 **Ambepityia G**, Kopelman PG, Ingram D, Swash M, Mills PG, Timmis AD. Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function. *J Am Coll Cardiol* 1990; **15**: 72-77 [PMID: 2295745 DOI: 10.1016/0735-1097(90)90178-R]

47 **Partamian JO**, Bradley RF. Acute myocardial infarction in 258 cases of diabetes. Immediate mortality and five-year survival. *N Engl J Med* 1965; **273**: 455-461 [PMID: 5826160 DOI: 10.1056/NEJM196508262730901]

48 **Bigger JT**, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. *Circulation* 1992; **85**: 164-171 [PMID: 1728446 DOI: 10.1161/01.CIR.85.1.164]

49 **Kleiger RE**, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol* 1987; **59**: 256-262 [PMID: 3812275 DOI: 10.1016/0002-9149(87)90795-8]

50 **Miettinen H**, Lehto S, Salomaa V, Mähönen M, Niemelä M, Haffner SM, Pyörälä K, Tuomilehto J. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. *Diabetes Care* 1998; **21**: 69-75 [PMID: 9538972 DOI: 10.2337/diacare.21.1.69]

51 **Katz A**, Liberty IF, Porath A, Ovsyshcher I, Prystowsky EN. A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction. *Am Heart J* 1999; **138**: 32-38 [PMID: 10385760 DOI: 10.1016/S0002-8703(99)70242-5]

52 **Sivieri R**, Veglio M, Chinaglia A, Scaglione P, Cavallo-Perin P. Prevalence of QT prolongation in a type 1 diabetic population and its association with autonomic neuropathy. The Neuropathy Study Group of the Italian Society for the Study of Diabetes. *Diabet Med* 1993; **10**: 920-924 [PMID: 8306587 DOI: 10.1111/j.1464-5491.1993.tb00007.x]

53 **Veglio M**, Borra M, Stevens LK, Fuller JH, Perin PC. The relation between QTc interval prolongation and diabetic complications. The EURODIAB IDDM Complication Study Group. *Diabetologia* 1999; **42**: 68-75 [PMID: 10027581 DOI: 10.1007/s001250051115]

54 **Givertz MM**, Sawyer DB, Colucci WS. Antioxidants and myocardial contractility: illuminating the "Dark Side" of beta-adrenergic receptor activation? *Circulation* 2001; **103**: 782-783 [PMID: 11171781 DOI: 10.1161/01.CIR.103.6.782]

55 **Iwai-Kanai E**, Hasegawa K, Araki M, Kakita T, Morimoto T, Sasayama S. alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. *Circulation* 1999; **100**: 305-311 [PMID: 10411857 DOI: 10.1161/01.CIR.100.3.305]

56 **Paulson DJ**, Light KE. Elevation of serum and ventricular norepinephrine content in the diabetic rat. *Res Commun Chem Pathol Pharmacol* 1981; **33**: 559-562 [PMID: 7330457]

57 **Soedamah-Muthu SS**, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). *Diabetes Care* 2008; **31**: 1360-1366 [PMID: 18375412 DOI: 10.2337/dc08-0107]

58 **Maser RE**, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. *Diabetes Care* 2003; **26**: 1895-1901 [PMID: 12766130 DOI: 10.2337/diacare.26.6.1895]

59 **Lykke JA**, Tarnow L, Parving HH, Hilsted J. A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. *Scand J Clin Lab Invest* 2008; **68**: 654-659 [PMID: 19378439 DOI: 10.1080/00365510802018330]

60 **Ziegler D**, Zentai CP, Perz S, Rathmann W, Haastert B, Döring A, Meisinger C. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. *Diabetes Care* 2008; **31**: 556-561 [PMID: 18086873 DOI: 10.2337/dc07-1615]

61 **Buse JB**, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC, Grimm RH, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. *Am J Cardiol* 2007; **99**: 21i-33i [PMID: 17599422 DOI: 10.1016/j.amjcard.2007.03.003]

62 **Pop-Busui R**, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Diabetes Care* 2010; **33**: 1578-1584 [PMID: 20215456 DOI: 10.2337/dc10-0125]

63 **Patel A**, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008; **358**: 2560-2572 [PMID: 18539916 DOI: 10.1056/NEJMoa0802987]

64 **Duckworth W**, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009; **360**: 129-139 [PMID: 19092145 DOI: 10.1056/NEJMoa0808431]

65 **Gerstein HC**, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008; **358**: 2545-2559 [PMID: 18539917 DOI: 10.1056/NEJMoa0802743]

66 **Cryer PE**. Hypoglycemia-associated autonomic failure in diabetes. *Handb Clin Neurol* 2013; **117**: 295-307 [PMID: 24095133 DOI: 10.1016/B978-0-444-53491-0.00023-7]

67 **Adler GK**, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. *Diabetes* 2009; **58**: 360-366 [PMID: 19056608 DOI: 10.2337/db08-1153]

68 **Bellmann B**, Tschöpe C. [Heart failure. Cardiovascular autonomic neuropathy in patients with diabetes mellitus]. *Herz* 2014; **39**: 306-311 [PMID: 24715197 DOI: 10.1007/s00059-014-4093-2]

69 **Boudina S**, Abel ED. Diabetic cardiomyopathy, causes and effects. *Rev Endocr Metab Disord* 2010; **11**: 31-39 [PMID: 20180026 DOI: 10.1007/s11154-010-9131-7]

70 **Pop-Busui R**, Cleary PA, Braffett BH, Martin CL, Herman WH, Low PA, Lima JA, Bluemke DA. Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT/EDIC study (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications). *J Am Coll Cardiol* 2013; **61**: 447-454 [PMID: 23265339 DOI: 10.1016/j.jacc.2012.10.028]

71 **Acar E**, Ural D, Bildirici U, Sahin T, Yılmaz I. Diabetic cardiomyopathy. *Anadolu Kardiyol Derg* 2011; **11**: 732-737 [PMID: 22137942 DOI: 10.5152/akd.2011.196]

72 **Ko SH**, Song KH, Park SA, Kim SR, Cha BY, Son HY, Moon KW, Yoo KD, Park YM, Cho JH, Yoon KH, Ahn YB. Cardiovascular autonomic dysfunction predicts acute ischaemic stroke in patients with Type 2 diabetes mellitus: a 7-year follow-up study. *Diabet Med* 2008; **25**: 1171-1177 [PMID: 19046195 DOI: 10.1111/j.1464-5491.2008.02567.x]

73 **Töyry JP**, Niskanen LK, Mäntysaari MJ, Länsimies EA, Uusitupa MI. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. *Diabetes* 1996; **45**: 308-315 [PMID: 8593935 DOI: 10.2337/diab.45.3.308]

74 **Ewing DJ**, Campbell IW, Clarke BF. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. *Ann Intern Med* 1980; **92**: 308-311 [PMID: 7356219 DOI: 10.7326/0003-4819-92-2-308]

75 **Ewing DJ**, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. *Diabetes Care* 1985; **8**: 491-498 [PMID: 4053936 DOI: 10.2337/diacare.8.5.491]

76 **Ewing DJ**, Campbell IW, Murray A, Neilson JM, Clarke BF. Immediate heart-rate response to standing: simple test for autonomic neuropathy in diabetes. *Br Med J* 1978; **1**: 145-147 [PMID: 620228]

77 **Pfeifer MA**, Cook D, Brodsky J, Tice D, Reenan A, Swedine S, Halter JB, Porte D. Quantitative evaluation of cardiac parasympathetic activity in normal and diabetic man. *Diabetes* 1982; **31**: 339-345 [PMID: 7152130 DOI: 10.2337/diab.31.4.339]

78 **Sandroni P**, Benarroch EE, Low PA. Pharmacological dissection of components of the Valsalva maneuver in adrenergic failure. *J Appl Physiol (1985)* 1991; **71**: 1563-1567 [PMID: 1757382]

79 **England JD**, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann D, Howard JF, Lauria G, Miller RG, Polydefkis M, Sumner AJ. Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). *Muscle Nerve* 2009; **39**: 106-115 [PMID: 19086069 DOI: 10.1002/mus.21227]

80 **Stranieri A**, Abawajy J, Kelarev A, Huda S, Chowdhury M, Jelinek HF. An approach for Ewing test selection to support the clinical assessment of cardiac autonomic neuropathy. *Artif Intell Med* 2013; **58**: 185-193 [PMID: 23768975 DOI: 10.1016/j.artmed.2013.04.007]

81 **Howorka K**, Pumprla J, Schabmann A. Optimal parameters of short-term heart rate spectrogram for routine evaluation of diabetic cardiovascular autonomic neuropathy. *J Auton Nerv Syst* 1998; **69**: 164-172 [PMID: 9696273 DOI: 10.1016/S0165-1838(98)00015-0]

82 **Bauer A**, Malik M, Schmidt G, Barthel P, Bonnemeier H, Cygankiewicz I, Guzik P, Lombardi F, Müller A, Oto A, Schneider R, Watanabe M, Wichterle D, Zareba W. Heart rate turbulence: standards of measurement, physiological interpretation, and clinical use: International Society for Holter and Noninvasive Electrophysiology Consensus. *J Am Coll Cardiol* 2008; **52**: 1353-1365 [PMID: 18940523 DOI: 10.1016/j.jacc.2008.07.041]

83 **Balcioğlu S**, Arslan U, Türkoğlu S, Ozdemir M, Cengel A. Heart rate variability and heart rate turbulence in patients with type 2 diabetes mellitus with versus without cardiac autonomic neuropathy. *Am J Cardiol* 2007; **100**: 890-893 [PMID: 17719340 DOI: 10.1016/j.amjcard.2007.03.106]

84 **Schnell O**, Muhr D, Weiss M, Dresel S, Haslbeck M, Standl E. Reduced myocardial 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients. *Diabetes* 1996; **45**: 801-805 [PMID: 8635656 DOI: 10.2337/diab.45.6.801]

85 **Stevens MJ**, Raffel DM, Allman KC, Dayanikli F, Ficaro E, Sandford T, Wieland DM, Pfeifer MA, Schwaiger M. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. *Circulation* 1998; **98**: 961-968 [PMID: 9737515 DOI: 10.1161/01.CIR.98.10.961]

86 **Stevens MJ**, Raffel DM, Allman KC, Schwaiger M, Wieland DM. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. *Metabolism* 1999; **48**: 92-101 [PMID: 9920151 DOI: 10.1016/S0026-0495(99)90016-1]

87 **Hamner JW**, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. *J Appl Physiol (1985)* 2001; **91**: 1199-1206 [PMID: 11509516]

88 **Vinik AI**, Erbas T. Recognizing and treating diabetic autonomic neuropathy. *Cleve Clin J Med* 2001; **68**: 928-30, 932, 934-944 [PMID: 11718432 DOI: 10.3949/ccjm.68.11.928]

89 **La Rovere MT**, Bigger JT, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. *Lancet* 1998; **351**: 478-484 [PMID: 9482439 DOI: 10.1016/S0140-6736(97)11144-8]

90 **Banthia S**, Bergner DW, Chicos AB, Ng J, Pelchovitz DJ, Subacius H, Kadish AH, Goldberger JJ. Detection of cardiovascular autonomic neuropathy using exercise testing in patients with type 2 diabetes mellitus. *J Diabetes Complications* 2013; **27**: 64-69 [PMID: 23083925 DOI: 10.1016/j.jdiacomp.2012.09.002]

91 **Spallone V**, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, Stevens M, Kempler P, Hilsted J, Tesfaye S, Low P, Valensi P. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. *Diabetes Metab Res Rev* 2011; **27**: 639-653 [PMID: 21695768 DOI: 10.1002/dmrr.1239]

92 **Dimitropoulos G**, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. *World J Diabetes* 2014; **5**: 17-39 [PMID: 24567799 DOI: 10.4239/wjd.v5.i1.17]

93 **Buse JB**, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Circulation* 2007; **115**: 114-126 [PMID: 17192512 DOI: 10.1161/CIRCULATIONAHA.106.179294]

94 **Kadoi Y**. Anesthetic considerations in diabetic patients. Part I: preoperative considerations of patients with diabetes mellitus. *J Anesth* 2010; **24**: 739-747 [PMID: 20640453 DOI: 10.1007/s00540-010-0987-1]

95 **Yajnik CS**, Kantikar V, Pande A, Deslypere JP, Dupin J, Calvet JH, Bauduceau B. Screening of cardiovascular autonomic neuropathy in patients with diabetes using non-invasive quick and simple assessment of sudomotor function. *Diabetes Metab* 2013; **39**: 126-131 [PMID: 23159130 DOI: 10.1016/j.diabet.2012.09.004]

96 **Ge X**, Pan SM, Zeng F, Tang ZH, Wang YW. A simple Chinese risk score model for screening cardiovascular autonomic neuropathy. *PLoS One* 2014; **9**: e89623 [PMID: 24621478 DOI: 10.1371/journal.pone.0089623]

97 **Howorka K**, Pumprla J, Haber P, Koller-Strametz J, Mondrzyk J, Schabmann A. Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy. *Cardiovasc Res* 1997; **34**: 206-214 [PMID: 9217892 DOI: 10.1016/S0008-6363(97)00040-0]

98 **Singh JP**, Larson MG, O'Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM, Levy D. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). *Am J Cardiol* 2000; **86**: 309-312 [PMID: 10922439 DOI: 10.1016/S0002-9149(00)00920-6]

99 **The Diabetes Control and Complications Trial Research Group.** The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. *Diabetes* 1996; **45**: 1289-1298 [PMID: 8826962 DOI: 10.2337/diab.45.10.1289]

100 **The Diabetes Control and Complications Trial Research Group.** The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. *Ann Intern Med* 1995; **122**: 561-568 [PMID: 7887548 DOI: 10.7326/0003-4819-122-8-199504150-00001]

101 Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. *JAMA* 2003; **290**: 2159-2167 [PMID: 14570951 DOI: 10.1001/jama.290.16.2159]

102 **Pop-Busui R**, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, Sommer C, Cleary PA, Lachin JM, Herman WH. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). *Circulation* 2009; **119**: 2886-2893 [PMID: 19470886 DOI: 10.1161/CIRCULATIONAHA.108.837369]

103 **Azad N**, Emanuele NV, Abraira C, Henderson WG, Colwell J, Levin SR, Nuttall FQ, Comstock JP, Sawin CT, Silbert C, Rubino FA. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). *J Diabetes Complications* 1999; **13**: 307-313 [PMID: 10765007 DOI: 10.1016/S1056-8727(99)00062-8]

104 **Charles M**, Fleischer J, Witte DR, Ejskjaer N, Borch-Johnsen K, Lauritzen T, Sandbaek A. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. *Diabetologia* 2013; **56**: 101-108 [PMID: 23064291 DOI: 10.1007/s00125-012-2744-5]

105 **Gaede P**, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. *Lancet* 1999; **353**: 617-622 [PMID: 10030326 DOI: 10.1016/S0140-6736(98)07368-1]

106 **Ziegler D**, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. *Diabetes Care* 1997; **20**: 369-373 [PMID: 9051389 DOI: 10.2337/diacare.20.3.369]

107 **Hu X**, Li S, Yang G, Liu H, Boden G, Li L. Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: systematic review and meta-analysis. *PLoS One* 2014; **9**: e87096 [PMID: 24533052 DOI: 10.1371/journal.pone.0087096]

108 **Ebbehøj E**, Poulsen PL, Hansen KW, Knudsen ST, Mølgaard H, Mogensen CE. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in Type I diabetic patients with abnormal albuminuria. *Diabetologia* 2002; **45**: 965-975 [PMID: 12136395 DOI: 10.1007/s00125-002-0869-7]

109 **Pousset F**, Copie X, Lechat P, Jaillon P, Boissel JP, Hetzel M, Fillette F, Remme W, Guize L, Le Heuzey JY. Effects of bisoprolol on heart rate variability in heart failure. *Am J Cardiol* 1996; **77**: 612-617 [PMID: 8610612 DOI: 10.1016/S0002-9149(97)89316-2]

110 **Didangelos TP**, Arsos GA, Karamitsos DT, Athyros VG, Georga SD, Karatzas ND. Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. *J Diabetes Complications* 2006; **20**: 1-7 [PMID: 16389160 DOI: 10.1016/j.jdiacomp.2005.05.002]

111 **Ozdemir M**, Arslan U, Türkoğlu S, Balcioğlu S, Cengel A. Losartan improves heart rate variability and heart rate turbulence in heart failure due to ischemic cardiomyopathy. *J Card Fail* 2007; **13**: 812-817 [PMID: 18068613 DOI: 10.1016/j.cardfail.2007.08.002]

112 **Korkmaz ME**, Müderrisoğlu H, Uluçam M, Ozin B. Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. *Am J Cardiol* 2000; **86**: 649-653 [PMID: 10980217 DOI: 10.1016/S0002-9149(00)01046-8]

**P-Reviewer:** Haidara M, Letsas K, Siu PM **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Cardiovascular autonomic reflex tests[1]**

|  |  |  |
| --- | --- | --- |
| Test | Technique | Normal response and values |
| Beat-to-beat HRV | With the patient at rest and supine, heart rate is monitored by ECG while the patient breathes in and out at 6 breaths per minute, paced by a metronome or similar device | A difference in heart rate of > 15 beats per minute is normal and < 10 beats per minute is abnormal.  The lowest normal value for the expiration-to inspiration ratio of the R-R interval decreases with age: age 20-24 yr, 1.17; 25-29, 1.15; 30-34, 1.13; 35-39, 1.12; 40-44, 1.10; 45-49, 1.08; 50-54, 1.07; 55-59, 1.06; 60-64, 1.04; 65-69, 1.03; and 70-75, 1.02 |
| Heart rate response to standing | During continuous ECG monitoring, the R-R interval is measured at beats 15 and 30 after standing | Normally, a tachycardia is followed by reflex bradycardia. The 30:15 ratio should be > 1.03 |
| Heart rate response to the Valsalva maneuver | The subject forcibly exhales into the mouthpiece of a manometer to 40 mmHg for 15 seconds during ECG monitoring | Healthy subjects develop tachycardia and peripheral vasoconstriction during strain and an overshoot bradycardia and rise in blood pressure with release. The normal ratio of longest R-R to shortest R-R is > 1.2 |
| Systolic blood pressure response to standing | Systolic blood pressure is measured in the supine subject. The patient stands and the systolic blood pressure is measured after 2 min | Normal response is a fall of < 10 mmHg, borderline fall is a fall of 10-29 mmHg and abnormal fall is a decrease of > 30 mmHg with symptoms. |
| Diastolic blood pressure response to isometric exercise | The subject squeezes a handgrip dynamometer to establish a maximum. Grip is then squeezed at 30% maximum for 5 min | The normal response for diastolic blood pressure is a rise of > 16 mmHg in the other arm |

HRV: Heart rate variability; ECG: Electrocardiogram.